MedTrace Logo

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT01802450 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-09-17

No results posted yet for this study

Summary

Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Dasatinib

Sponsors & Collaborators

  • Dynamic Solutions

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Steegmann Juan Luis, Dr · PETHEMA Foundation

  • García Valentín, Dr · PETHEMA Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-06-30
Completion
2016-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802450 on ClinicalTrials.gov